Related NewsAll news
EORTC 1809 STRASS II trial in retroperitoneal sarcoma receives support by the Anticancer Fund
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment
International Randomised Controlled Trial of Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Incorporating the patient voice in sarcoma research: How can we assess quality of life in this heterogeneous group of patients?
A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
In recent years, EORTC has been involved in a number of large practice-changing clinical trials in the field of Soft Tissue and Bone, leading to the registration of drugs to treat sarcomas including gastrointestinal stromal tumors (GIST). The following compounds were investigated within this group (STBSG):
- Imatinib for GIST
- Trabectedin for all types of STS
- Pazopanib for non-adipocytic STS
- Eribulin for liposarcomas More information
Multicentre trials, with large patient numbers to influence clinical practice and address important research topics, evaluated the role of adjuvant chemotherapy in soft tissue sarcoma patients as well as the role of single-agent doxorubicin versus the combination of doxorubicin plus ifosfamide in advanced and/or metastatic STS patients.
- EORTC-1637 (lms retrospective): retrospective evaluation of first-line treatment for advanced, metastatic or unresectable leiomyosarcomas.
(project leader: lorenzo d’ambrosio)
Status: database open
This is a retrospective research project (rp) to evaluate the activity of doxorubicin as monotherapy as well as in combination with ifosfamide or dacarbazine as first-line treatment for leiomyosarcoma, pleomorphic leiomyosarcoma and undifferentiated sarcoma with smooth muscle differentiation, to potentially guide the design of a prospective randomized study.
As of today, we have already into our database.
Please be noted that we are planning to close the database by the end of march.
- EORTC-1647 (angio. retrospective): retrospective evaluation of adjuvant chemotherapy in angiosarcoma.
(project leader: robin jones)
Research project approved: 23 aug. 2016
The primary objective of the study will be to evaluate the activity of adjuvant chemotherapy in angiosarcoma patients and to potentially guide the design of a prospective randomized study.
Several sites (around 41) from the STBSG are planning to contribute patient data from their clinical practice.
FP7 EUROSARC – European Clinical Trials in Rare Sarcomas within an integrated translational trial network. EUROSARC aims to validate novel local and systemic treatment strategies in localized phase sarcomas, and innovative targeted therapies in advanced phase sarcomas based on the scientific understanding of molecular alterations driving the tumors. Several clinical trials are involved including EORTC trial 62092-22092-STRASS A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas.
FP7 EEC EURO EWING – International Clinical Trials to Improve Survival from Ewing Sarcoma. EEC EURO EWING aims to improve treatment outcomes for patients with Ewing sarcoma, a rare cancer. The program comprises two clinical trials testing different chemotherapy treatments for this rare disease: trial EORTC 1402 “International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing’s Sarcoma Family of Tumours – Euro Ewing 2012” and trial EORTC 1403 “International Randomised Controlled Trial of Chemotherapy for the treatment of Recurrent and Primary Refractory Ewing Sarcoma – rEECur”.
European Reference Networks (ERN) for rare solid tumours (EURACAN). EURACAN is involving references centers in Europe covering ten types of rare cancers. EURACAN will improve patient cares and facilitate research in rare cancers. EORTC is providing the clinical research infrastructure. (No website available yet)
Mannheim University Medical Center
Winan van Houdt
The Netherlands Cancer Institute
Centre Léon Bérard
E. Wardelmann - Muenster , DE
Chair Pathology and Translational Research
Gerhard Domagk Institute of Pathology - University Hospital Muenster
P. Huang - London, GB
Vice-Chair of the Pathology and Translational Research
Institute for Cancer Research – Laboratory
D. Strauss - London , GB
Chair Local Treatment
Royal Marsden Hospital
S. Stacchiotti - Milano, IT
Chair Systemic Treatment
Fondazione IRCCS Istituto Nazionale dei Tumori
C. Messiou - London , GB
Chair Imaging Subcommittee
Royal Marsden Hospital
O. Husson - Nijmegen, NL
Chair Quality of Life Subcommittee
Radboud University Medical Center Nijmegen
L. d’Ambrosio - Candiolo, IT
Instituto di Candiolo – IRCCS
S. Ford - Birmingham, GB
UHB, Queen Elisabeth Medical Centre
G. Marquina - Madrid, ES
Hospital Universitario San Carlos
J. Stelmes - Zurich, CH
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS)
Randomized phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy. EORTC-1506-STBSG “ANITA”
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas
Survival prediction models since liver transplantation - comparisons between Cox models and machine learning techniques
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)